Search Results for "Sjogren A Belimumab"

05:26 EST 20th December 2014 | BioPortfolio

Original Source: Efficacy and Safety of Belimumab in Subjects With Primary Sjögren's Syndrome

Sjögren's syndrome (SS) is a systemic autoimmune disease characterized by an increase in BAFF (BLyS) levels and a resulting B cell hyperactivity. B cells are involved in the pathogenesis of SS in both systemic and glandular features, and B cell downregulation may lead to a decrease of disease activity. Moreover, pathogenesis of SS is closed to that of Systemic lupus erythematosus, where Belimumab has been proven to be effective.

Matching Channels

None

Matching News

Pacific Mercantile Bank Names Robert E. Sjogren Chief Operating Officer

COSTA MESA, Calif., Sept. 8, 2014 (GLOBE NEWSWIRE) -- Pacific Mercantile Bank ("the Bank"), the wholly owned subsidiary of Pacific Mercantile Bancorp (Nasdaq:PMBC), today announced that Robert E. Sjo...

Human medicines European public assessment report (EPAR): Benlysta, belimumab, Revision: 10, Authorised

Human medicines European public assessment report (EPAR): Benlysta, belimumab, Revision: 9, Authorised

Aldeyra Therapeutics Announces Collaboration With the National Organization for Rare Disorders to Enhance Awareness for Sjogren-Larsson Syndrome Patients

LEXINGTON, Mass., Dec. 4, 2014 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free...

Link between viral infection and autoimmune disease

Australian scientists have discovered that common viral infections can pave the way to autoimmune disease. Their work was published in the journal Immunity. The research focused on chronic cytomegalo...

NIHR Announces Pioneering Study to Test New Treatment for Sjogren’s Syndrome

The National Institute for Health Research (NIHR) has today announced the start of the UK’s first commercial trial of a new treatment for Sjogren’s syndrome. Up to half...

Autoimmune Technologies, LLC - Product Pipeline Analysis, 2014 Update

Recently added to the BioPortfolio report store, Autoimmune Technologies, LLC - Product Pipeline Analysis, 2014 Update is a new report from GlobalData published on 2014-07-14. This 23-page report is ...

Dr. Herbert Baraf Recognized by the American College of Rheumatolgoy

Herbert S.B. Baraf, MD, managing partner of Arthritis & Rheumatism Associates, was honored with the Phelps Award from the American College of Rheumatology. Wheaton MD (PRWEB) December 11, 2014 Co...

Matching PubMed Articles

Update on belimumab for the management of systemic lupus erythematosus.

Introduction: Belimumab is a fully humanised mAb against B lymphocyte stimulator (B-LyS). It is the first biological drug to be licensed and approved by the US FDA and the European Medicines Evaluatio...

Successful application of belimumab in two patients with systemic lupus erythematosus experiencing a flare during tocilizumab treatment.

This case report describes two female lupus patients who both received biological treatment with tocilizumab and with belimumab. The disease course was remarkably similar in both cases. Tocilizumab re...

A23: favorable response to belimumab in childhood-onset systemic lupus erythematosus.

Belimumab (Benlysta) is a human monoclonal antibody inhibiting soluble B-lymphocyte stimulator that was approved by the Food and Drug Administration in 2011 for treatment of active, autoantibody-posit...

RESPIRATORY LESIONS DUE TO SJOGREN SYNDROME.

New treatments for inflammatory rheumatic disease.

As our understanding of the pathogenesis of autoimmune diseases is growing, new therapies are being developed to target disease-specific pathways. Since the introduction of etanercept in 1998, several...

Search Whole site using Google

Loading
Search BioPortfolio:
Loading
Advertisement
Advertisement
Advertisement Advertisement